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The incidence of fungal infections has been grossly underestimated in the past decades as
a consequence of poor identification techniques and a lack of regular epidemiologic surveys in
low- and middle-income countries. The most affected areas of the world are the countries where
some routinely administrated and effective antifungal drugs are not available, especially for people
under living standards [1]. Approximately one quarter of the worldwide population suffers from
superficial mycoses [2], which is the fourth most common illness on Earth after headaches and dental
caries [3]. In the immunocompetent patient, cutaneous fungal infections are non-life-threatening,
but associated with social embarrassment and stigma [1], because they might be recurrent and difficult
to eradicate [4]. Patients who suffer from impaired and weak immune status due to infections (e.g.,
HIV), hematological malignancies, who receive immunosuppressive therapy or necessitate intensive
care (e.g., organ transplantation) are at high risk for microbial infections in general and more specifically
to develop severe invasive mycoses, such as aspergillosis, candidiasis, cryptococcosis, histoplasmosis,
talaromycosis and pneumocystosis with fatal outcome [5,6]. It has been estimated that the number of
people that die from fungal diseases per year is > 1.5 million and outreaches the numbers that die from
tuberculosis or malaria [2].
Plant pathogenic fungi also pose severe risk to human and animal health, and food supply.
Crops, worth billions of € per year, are destroyed by plant pathogenic fungi that constitute the main
group of phytopathogens. Mycotoxin-contaminated crops, vegetables, fruits, and animal feeds are
continuously increasing in Europe in the last years [7]. Moreover, fungal bio-deterioration of buildings,
paintings, object arts and books also have impact on our cultural heritage [8]; furthermore, indoor
molds affect human health with impairing the immune status of healthy individuals [9]. Finally,
the emergence of novel fungal diseases in plants and animals, as a result of climate change, is affecting
global sustainability and biodiversity [10,11].
The number of effective antifungal drugs to prevent fungal contaminations and treat
life-threatening mycoses is modest in comparison to the armamentarium available for antibacterial
treatment strategies [12]. The high similarity between fungal pathogen and host in terms of cellular
morphology, physiology and metabolism hampers the identification and development of new
compounds that interfere with targets that are unique to fungi and guarantee improved tolerance or
at least minimize severe side effects in the host. Consequently, pesticides and feed supplements in
agriculture and animal breeding to prevent or reduce fungal infections belong to the same class of
active agents that are also applied in human medical treatment. Since the early 1990’s, when triazoles
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were introduced in antifungal therapy, a pronounced increase in Candida and Aspergillus species was
observed that were less susceptible or even resistant to these licensed drugs [13,14]. In contrast to
fungi that are intrinsically resistant against certain drug classes (e.g., non-albicans Candida species,
NAC) or are multidrug-resistant (e.g., Candida glabrata [15], Candida auris [16], Fusarium solani [17],
and Lomentospora (formerly Scedosporium) prolificans [18]), a resistance mechanism can also be acquired
following repeated and long-term exposure to antifungal drugs. This accounts for iatrogenic azole
resistance development in fungi but also the emergence of azole-resistant aspergillosis as a consequence
of wide agricultural use of this class of antifungal drugs [19]. In the latter case azole therapy may
fail in the host who has never been treated with azoles before, but suffers from infection with an
azole-resistant Aspergillus fumigatus environmental strain [20].
Thus, early and accurate diagnosis is essential to promote the proper administration of the most
effective antifungal therapy and reduce morbidity and mortality. In parallel, effective surveys need
to be implemented that ensure the use of fungicides in food production and animal and human
medicine. Furthermore, collaborative efforts are required to identify and develop new compounds
with high fungal specificity and novel antifungal mechanisms to overcome the limitations of resistance
development and adverse toxicity in the host.
In this respect, nature constitute a rich source for proteins and peptides that promise future
drug development. Small, cysteine-rich, cationic proteins that are produced by the most diverse
organisms throughout the phylogenetic tree are potential candidates for new antifungal medicines and
therapeutic strategies [21]. Most promising thereby are antimicrobial proteins and peptides (AMPs)
originating from filamentous fungi belonging to the class Eurotiomycetes (division Ascomycota).
Numerous representatives have been extensively analyzed to date, reviewed in [22–25] and even more
await their identification and characterization as the genomes of filamentous ascomycetes harbor
information for still unidentified proteins with antimicrobial potential [26–29]. Deep mining of fungal
genome databases and accurate phylogenetic analyses promote these efforts [29]. One obstacle in
protein isolation might be the unknown gene regulation and/or very low protein expression levels.
This, however, can be overcome by using (heterologous) expression systems that allow the generation
and purification of recombinant proteins in sufficient quantity and of high quality that ensure thorough
characterization of their structure and function [27,30]. Also, chemical synthesis has been developed
for cysteine-rich AMPs, coping with the challenge of correct disulfide bonding within the protein
during the synthesis process [31,32].
AMPs from Eurotiomycetes share common features: (i) they are encoded as pre-pro proteins
with a signal- and a pro-sequence, which both are cleaved during protein processing and secretion
into the culture broth; (ii) the mature proteins consist of ca. 50–60 amino acids (Mw: ~6000 Da),
lack any posttranslational modifications, and three to four disulfide bridges stabilize a compact β-fold
structure; (iii) all proteins investigated in detail so far exhibit high stability against harsh environmental
conditions and (iv) exclusively inhibit the growth of human- and plant-pathogenic fungi in a fungistatic
and/or fungicidal manner at µM concentrations [21]. In addition, antiviral activity has been reported
in one case [33]. However, some differences exist in species specificity, antifungal efficacy, and mode of
action, which are distinct from that of conventional antifungal drugs [21].
Their antifungal mechanisms are intensively studied nowadays. On the one hand, the use of
genetically manipulated fungal strains allowed to define pathways involved in protein toxicity [34–38].
On the other hand, comprehensive nuclear magnetic resonance analyses provided detailed knowledge
on the solution structure of AMPs and proposed protein motifs that might play an important role in
protein function and host interaction [32,33,39,40]. Unfortunately, no fungal-specific target molecule for
AMPs has been identified so far, which restrains the development of new, safely applicable AMP-based
antifungal strategies. However, the availability of accurate AMP solution structures deposited in the
protein data bases (such as the worldwide Protein Data Bank [41]) provide a valuable source for in
silico homology modelling and molecular dynamics simulations to propose not only the structure
of uncharacterized AMP candidates but also the mechanistic way of action [42]. These structural
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and functional predictions pave the way towards the modification of natural proteins and peptides
applying rational design tools or combinatorial approaches to generate novel AMPs with improved
efficacy against plant and human pathogenic fungi [29,32,43,44]. As the chemical synthesis of peptides
and proteins becomes more cost-effective [45], AMPs and short peptide derivatives have significant
commercial potential on the global market to be produced and applied as new antifungal compounds
in the future [46].
In vitro and in vivo experiments approved fungal AMP tolerance of mammalian and plant cells
and efficacy in reducing fungal pathogen load in plant, fruit, and animal models, corroborating their
suitability for the development of new antifungal strategies in medical treatment, plant protection and
food preservation [25,29,33,47–65].
Apart from the AMPs originating from fungi of the class Eurotiomycetes, small antimicrobial
peptides from various mitosporic filamentous fungi belonging to the genus Trichoderma (class
Sordariomycetes) have been characterized that form a unique class of so-called peptaibols. These small
peptides (ca. 5–20 amino acid long; Mw: ~500–2200 Da) contain unusual amino acids and are
synthesized by non-ribosomal peptide synthases. Their antibacterial and antifungal activity is closely
linked with a helical structure, that favors aggregation and ion channel formation in lipid bilayers
causing membrane damage [66–69].
In this Special Issue on "Antimicrobial Proteins in Filamentous Fungi", the contributors addressed
achievements in this research field and posed questions that need to be answered to better understand
the nature of AMPs and to push forward the development of novel AMP-based antimicrobial strategies
and to overcome antimicrobial resistance.
Heredero et al. aimed in their work at the rational design of chimeric protein:peptide molecules
with improved antifungal efficacy. The combination of the Penicillium digitatum AMP AfpB with
the hexapeptide PAF26 resulted in biotechnologically produced protein chimeras that allowed new
insights into AMP design, structure, and function [70].
The paper of Marik et al. focuses on the characterization of new peptaibols from Trichoderma
gamsii and Trichoderma koningiopsis, belonging to clade Viride, showing variations in antimicrobial
activity that can be assigned to differences in the cell wall structure of the target organisms [71].
The study by Delgado et al. proved the potential of a Penicillium chrysogenum AMP, the PgAFP in
food protection. PgAFP combined with the food ripening-yeast Debaryomyces hansenii effectively
reduced Aspergillus parasiticus growth and aflatoxin contamination in dry-fermented sausage
and cheese [72].
Unravelling the AMP structure and function provides important information for the improvement
of AMP efficacy and the development of new treatment strategies by rational drug design. An overview
on structure peculiarities of β-strand disulfide AMPs from ascomycetous origin and possibilities of
their production by modern synthetic chemistry methods and recombinant technology is given in the
mini-review by Váradi et al. [73].
Finally, the review of Meyer and Jung [74] compares structure and function of AMPs from
Ascomycetes with those of bacterial cannibal toxins and redirects our narrow human conception of
AMPs as purely bioactive molecules towards their important role in controlling different cellular
processes to ensure optimal fitness of the producing fungal organism.
In conclusion, we want to thank all contributors to this Special Issue on AMPs in filamentous fungi
for their participation. The papers published in this Special Issue provide a most valuable overview
on the functional and structural complexity of the members of this AMP group and reflects the big
efforts made by this community to unravel the most divers aspects in understanding fungal AMPs.
This should encourage the worldwide scientific community engaged in AMP science to specifically
expand their attention towards AMPs from filamentous fungi, many of which still await identification
and characterization.
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